SomaLogic announces new SomaScan 11k platform

SomaLogic announced the launch of its high-plex proteomics platform, which provides 11,000 total protein measurements. The SomaScan 11K Platform is the largest proteomics offering available on the market. The new high-plex platform is expected to give researchers a considerable edge in the discovery of biomarkers and drug targets for translational medicine. Proteins make up more than 90% of all known drug targets and having a broader view of the human proteome, provided by SomaLogic’s 11K platform, gives researchers more opportunities to make unique and novel biological discoveries. The aptamer-based platform retains the previous version’s low coefficients of variation versus the 10-to-20% in antibody-based platforms. This gives researchers more accuracy with fewer, smaller samples, which is often critical in population studies with limited sample sizes. “Our research teams expanded the SomaLogic SomaScan Platform from covering 7,000 proteins to 11,000 proteins-over half of the human proteome,” said SomaLogic Chief Executive Officer Adam Taich. “Consistent with every expansion of our SomaScan menu size, our scientists focused on maintaining the platform’s reproducibility, sensitivity and specificity across a 10-log dynamic range.”